Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMID 14517071)

Published in Virology on September 15, 2003

Authors

Mojgan H Naghavi1, Piotr Nowak, Jan Andersson, Anders Sönnerborg, Huan Yang, Kevin J Tracey, Anders Vahlne

Author Affiliations

1: Division of Clinical Virology, F68, Karolinska Institutet, Huddinge University Hospital, S-141 86 Stockholm, Sweden. mn2034@columbia.edu

Articles citing this

HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol (2012) 2.75

Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood (2007) 1.93

HMGB1 in health and disease. Mol Aspects Med (2014) 1.67

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol (2009) 1.26

BCL11B is a general transcriptional repressor of the HIV-1 long terminal repeat in T lymphocytes through recruitment of the NuRD complex. Virology (2008) 1.01

High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med (2012) 0.97

HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells. Cell Death Differ (2011) 0.96

Mechanism of high-mobility group protein B enhancement of progesterone receptor sequence-specific DNA binding. Nucleic Acids Res (2008) 0.94

Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology (2007) 0.88

The association of HMGB1 gene with the prognosis of HCC. PLoS One (2014) 0.87

Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2015) 0.81

Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci (2011) 0.81

Unbiased proteomic analysis of proteins interacting with the HIV-1 5'LTR sequence: role of the transcription factor Meis. Nucleic Acids Res (2012) 0.80

HMGB1 Promotes Hepatitis C Virus Replication by Interaction with Stem-Loop 4 in the Viral 5' Untranslated Region. J Virol (2015) 0.78

Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1. Proc Natl Acad Sci U S A (2012) 0.77

Porcine epidemic diarrhea virus nucleoprotein contributes to HMGB1 transcription and release by interacting with C/EBP-β. Oncotarget (2016) 0.75

Purification and characterization of transcription factors. Mass Spectrom Rev (2013) 0.75

Articles by these authors

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature (2002) 12.09

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57

Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14

The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86

Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med (2004) 6.38

HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23

Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science (2011) 5.87

Sepsis definitions: time for change. Lancet (2013) 5.63

Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71

HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53

A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80

Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2003) 3.75

Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68

Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med (2006) 3.66

Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med (2007) 3.63

Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med (2005) 3.58

Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med (2007) 3.27

Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med (2006) 3.26

Novel role of PKR in inflammasome activation and HMGB1 release. Nature (2012) 3.13

The cytokine activity of HMGB1. J Leukoc Biol (2005) 3.02

Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med (2005) 3.01

HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology (2002) 2.95

HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood (2006) 2.95

The "cytokine profile": a code for sepsis. Trends Mol Med (2005) 2.89

Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89

Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol (2010) 2.88

Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med (2002) 2.83

Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (2012) 2.79

Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood (2003) 2.70

Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell (2013) 2.69

Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A (2008) 2.58

Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2003) 2.54

Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol (2003) 2.50

The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology (2006) 2.47

High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2006) 2.44

Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med (2007) 2.41

Network of dynamic interactions between histone H1 and high-mobility-group proteins in chromatin. Mol Cell Biol (2004) 2.33

High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol (2004) 2.32

Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med (2003) 2.30

Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27

Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26

High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages. Anesthesiology (2014) 2.24

IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol (2003) 2.24

The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol (2013) 2.22

Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19

Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods (2004) 2.14

The cholinergic anti-inflammatory pathway. Brain Behav Immun (2005) 2.13

Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12

Targeting HMGB1 in inflammation. Biochim Biophys Acta (2009) 2.11

ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 2.11

Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A (2006) 2.08

HMGB1 as a DNA-binding cytokine. J Leukoc Biol (2002) 2.07

Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci U S A (2006) 2.06

Reflex principles of immunological homeostasis. Annu Rev Immunol (2012) 2.04

The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis (2005) 2.02

Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol (2007) 2.02

The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med (2003) 2.00

Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol (2005) 1.97

Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol Med (2008) 1.97

Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J Vasc Surg (2002) 1.89

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr (2007) 1.88

Neural reflexes in inflammation and immunity. J Exp Med (2012) 1.87

Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock (2006) 1.80

Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80

Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med (2007) 1.80

Lymphocyte-derived ACh regulates local innate but not adaptive immunity. Proc Natl Acad Sci U S A (2013) 1.78

HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps. PLoS One (2013) 1.77

Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A (2006) 1.75

The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med (2009) 1.73

RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med (2007) 1.71

Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun (2008) 1.70

Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood (2012) 1.69

Rethinking inflammation: neural circuits in the regulation of immunity. Immunol Rev (2012) 1.68

Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS (2002) 1.67